Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorect
A single arm, prospective, single center Phase1/2 Dietary intervention trial for subjects diagnosed with colorectal cancer and scheduled for tumor resection more than 21 days from informed consent. Subjects will be provided 21 days of standardized High-fiber/low-fat meals and complete a food diary up until lunch on the
| Condition(s) | Colorectal Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | A single arm, prospective, single center Phase1/2 Dietary intervention trial for subjects diagnosed with colorectal cancer and scheduled for tumor resection more than 21 days from informed consent. Subjects will be provided 21 days of standardized High-fiber/low-fat meals and complete a food diary up until lunch on the day prior to surgery. Blood samples will be collected at baseline and on the day of surgery. Stool samples will be collected throughout the dietary intervention period at specific timepoints, on the day of surgery, and 30 days post-surgery. Tissue from the tumor resection will be isolated for organoid cultures. Subjects will be followed per standard of care for up to 5 years or disease recurrence, whichever comes first. Subject may be treated for their cancer prior to surger |
| Who can participate | Inclusion Criteria: * Must have histologically or cytologically confirmed colorectal adenocarcinoma. * Planned for primary tumor resection at the University of Chicago Medicine ≥21 from date of obtained informed consent. Patients with metastatic disease but undergoing primary site resection are eligible for the study. * Age ≥18 years. * Patients \<18 years of age, children are excluded from this study, because they have unique nutritional requirements that might not be met by with the standardized diet. The food in the diet is designed for adults and would not be feasible for children, especially those attending school. In addition, colon cancer is extremely rare in children. * May have received neoadjuvant therapy (chemotherapy, radiation). * Patients with Hepatic arterial infusion (HAI) |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Chicago |
| Locations | Chicago, Illinois, United States |
| Start date | 2024-06-27 |
| NCT ID | NCT06349590 |
| Official listing | https://clinicaltrials.gov/study/NCT06349590 |